Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis

ABSTRACT

The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator. The results of the study suggest that ABL increases bone mineral density more than TPD and reduces major osteoporotic fractures to a greater extent than TPD with a more rapid onset of action. These outcomes combined with a positive safety profile make ABL an interesting addition to the armamentarium against postmenopausal osteoporosis.

KEYWORDS:

• Abaloparatide
• anabolic agents
• fracture
• hypercalcemia
• osteoporosis
• parathyroid hormone
• teriparatide

Declaration of interest

J.Y Reginster has received consultancy fees participated in paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre; lecture fees when speaking at the invitation of the sponsor from IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council (DRC); and grant support from industry via his institution from IBSA-Genevrier, Mylan, CNIEL, Radius Health. N.M Al Daghri has received support from the Prince Mutaib Chair for Biomarkers of osteoporosis, Deanship of Scientific Research Chairs, King Saud University, Riyadh, Saudi Arabia. O. Bruyere has received grant support or consulting fees from Bayer, Genevrier, IBSA, Meda, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, SMB and TRB Chemedica. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper did not received funding.